Marketed Products HIV/AIDS. Liver Diseases

Transcription

1

2 Marketed Products Following is a summary of Gilead s product portfolio. For safety information on these products see full Prescribing Information, including BOXED WARNINGS for certain products, on Gilead.com. HIV/AIDS Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a combination of Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. (U.S. approval, 2004; EU approval, Japan Tobacco Inc. commercializes the product in Japan.) Once-daily Truvada is also indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. (U.S. approval, 2012; EU approval, 2016.) For prescribing considerations, please see the full Prescribing Information for Truvada. Viread (tenofovir disoproxil fumarate) 300 mg is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in Japan Tobacco Inc. commercializes the product in Japan.) Viread is also indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 12 years of age and older. (U.S. and EU approval, 2008.) Liver Diseases Sovaldi (sofosbuvir) 400 mg is an HCV nucleotide analog NS5B polymerase inhibitor indicated for the treatment of CHC infection as a component of a combination antiviral 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection. (U.S. approval, 2013; EU approval, 2014.) 2

3 Research compounds have not been established. HIV/AIDS Phase 1 Phase 2 Phase 3 Bictegravir/F/TAF (integrase strand transfer inhibitor/ emtricitabine/tenofovir alafenamide) Potential Indication: HIV/AIDS Emtricitabine/tenofovir alafenamide Potential Indication: PrEP GS-9620 (TLR-7 agonist) Potential Indication: HIV/AIDS Liver Diseases Sofosbuvir, velpatasvir and voxilaprevir (pan-genotypic NS3 protease inhibitor) Potential Indication: Chronic HCV Infection Phase 1 Phase 2 Phase 3 US and EU Regulatory Submission GS-4997 (ASK-1 inhibitor) Potential Indication: NASH GS-4997 (ASK-1 inhibitor) Potential Indication: Alcoholic Hepatitis GS-9620 (TLR-7 agonist) Potential Indication: Chronic HBV Infection GS-9674 (FXR agonist) Potential Indications: NASH; Primary Biliary Cirrhosis; Primary Sclerosing Cholangitis GS-0976 (ACC inhibitor) Potential Indication: NASH 3

4 Hematology/Oncology Idelalisib (PI3K delta inhibitor) Potential Indication: Relapsed Refractory Chronic Lymphocytic Leukemia Phase 1 Phase 2 Phase 3 GS-5745 (MMP9 mab inhibitor) Potential Indication: Gastric Cancer Entospletinib (Syk inhibitor) Potential Indications: Hematological Malignancies; Acute Myeloid Leukemia GS-4059 (BTK inhibitor) Potential Indication: B-cell Malignancies GS-5745 (MMP9 mab inhibitor) Potential Indication: Solid Tumors GS-5829 (BET inhibitor) Potential Indication: Solid Tumors /Respiratory Phase 1 Phase 2 Phase 3 Filgotinib (JAK1 inhibitor) Potential Indications: Rheumatoid Arthritis; Crohn s Disease; Ulcerative Colitis Filgotinib (JAK1 inhibitor) Entospletinib (Syk inhibitor) Potential Indication: Chronic Graft Versus Host Disease Presatovir (fusion inhibitor) Potential Indication: Respiratory Syncytial Virus GS-5745 (MMP9 mab inhibitor) Potential Indications: Rheumatoid Arthritis; Cystic Fibrosis GS-9876 (Syk inhibitor) Potential Indication: Rheumatoid Arthritis Other Phase 1 Phase 2 Phase 3 GS-5734 (Nuc inhibitor) Potential Indication: Ebola Virus Infection 4

5 Responsibility As Gilead grows as a company, we strive to play our part in expanding global access to our medications and to provide support to the communities in which we operate. Global Access Programs Gilead recognizes the urgent need for access to our medications worldwide, particularly in developing countries where the AIDS epidemic and other health challenges are devastating communities. We operate access programs to provide our HIV and viral hepatitis medications at substantially reduced prices in 134 low- and middle-income countries. We also coordinate and support educational activities for medical and clinical workers to ensure proper use of our medicines. As a result, approximately 10 million patients in the developing world are receiving Gilead s therapies for HIV/AIDS. Gilead is also working with regional partners and generic manufacturers to scale up distribution of discounted hepatitis C medicines in low- and middle-income countries, adopting a systematic country-by-country approach that initially prioritizes those with the highest disease burden. Partnerships with Generic Manufacturers and Medicines Patent Pool Gilead has signed non-exclusive licenses with multiple generic manufacturers, granting them rights to produce highquality, low-cost generic versions of certain Gilead medicines for HIV/AIDS and chronic hepatitis B and C. Partners have also been granted rights to produce generic versions of new Gilead therapies once they receive U.S. regulatory is working to increase global access to high-quality, low-cost antiretroviral therapy through the sharing of patents. The Patent Pool has been granted similar licensing terms for Gilead HIV medicines as our generic manufacturing partners. Fighting Visceral Leishmaniasis in the Developing World We have worked closely with the World Health Organization (WHO) and non-governmental organizations since 2011 to provide AmBisome at a preferential price for the treatment of visceral leishmaniasis (VL) in resource-limited settings. VL is the second-largest parasitic killer in the world after malaria, responsible for approximately 40,000 deaths each years to expand access to diagnostics and treatment for VL. Patient Access in China In China, we plan to launch a special charitable fund to provide funding support for related projects and activities, helping improve access to medicines by eliminating barriers to medical treatment for the vulnerable groups. Meanwhile, we also provide continuing education support to Chinese medical professionals. Screening, Diagnosis and Linkages to Care Gilead is actively involved in several community partnerships that focus on expanding screening programs, encouraging patients to take an active role in their treatment and linking them to prompt, appropriate medical care. In 2010, Gilead launched the FOCUS Program, which partners with healthcare providers, government agencies and community organizations across the United States to develop replicable model programs to routinize HIV screening and linkage to care. Gilead is now supporting partner organizations to apply the FOCUS model to screening and linkage to care for hepatitis C, with the goal of identifying replicable programs that can be applied broadly. Gilead is also helping to strengthen community-level public health efforts to expand screening programs for hepatitis B. In the United States, this work focuses on Asian American 5

6 The Gilead Foundation of underserved communities in the United States and internationally. The Foundation s giving focuses on expanding access to HIV and hepatitis education, outreach, prevention and health services. Strength Through Partnership C ollaborations with partners in science, academia, business and local communities are central to our work. Leadership The following individuals comprise Gilead s Senior Management Team. See Gilead.com for biographies and a listing of members of the company s Board of Directors. John F. Milligan, PhD John C. Martin, PhD Executive Chairman Gregg H. Alton Executive Vice President, Commercial and Access Operations ALA, Corporate and Medical Affairs Norbert W. Bischofberger, PhD Executive Vice President, Research and Rogers Luo Vice President & General Manager, China Andrew Cheng, MD, PhD Executive Vice President, Clinical Research and Development Operations William A. Lee, PhD Executive Vice President, Research John McHutchison, MD Executive Vice President, Clinical Research Jim Meyers Executive Vice President, Worldwide Commercial Operations Brett Pletcher Executive Vice President and General Counsel Martin Silverstein, MD Executive Vice President, Strategy Robin L. Washington Executive Vice President and Chief Financial Katie L. Watson Executive Vice President, Human Resources Taiyin Yang, PhD Executive Vice President, Pharmaceutical Development and Manufacturing Kevin Young CBE Growing Worldwide Footprint We have operations in the following locations: North America Foster City, CA (Corporate Headquarters) Fremont, CA Oceanside, CA San Dimas, CA Branford, CT Miami, FL Seattle, WA Alberta, Canada Ontario, Canada Mexico City, Mexico South America Argentina Brazil Asia China Hong Kong India Japan Korea Singapore Taiwan Africa South Africa Australia Australia/New Zealand Europe Stockley Park, UK Cambridge, UK London, UK Austria Belgium Czech Republic Denmark Finland France Germany Greece Ireland Israel Italy Netherlands Norway Poland Portugal Russia Slovakia Spain Sweden Switzerland Turkey Middle East United Arab Emirates More Information For more information about Gilead, please contact Phone infochina@gilead.com Or follow Gilead on WeChat by scanning the QR code below Gilead. All rights reserved.